Chelation therapy in cardiovascular disease: Ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane

Journal of Clinical Pharmacology

Volumn 38, Issue 2, 1998, Pages 101-105

  Elihu, Nadia ^a   Anandasbapathy, Sharmila ^a   Frishman, William H ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DEFEROXAMINE; DOXORUBICIN; EDETIC ACID; FLUOROURACIL; RAZOXANE;

ATHEROSCLEROSIS; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CARDIOMYOPATHY; CARDIOTOXICITY; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; EYE TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON OVERLOAD; LUNG TOXICITY; OTOTOXICITY; PERIPHERAL VASCULAR DISEASE; REPERFUSION INJURY; REVIEW;

EID: 0031882531     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04397.x     Document Type: Review

References (51)

1. Grier MT, Meyers DG: So much writing, no little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 1993;27:1504-1509.
2. Olszewer E, Sabbag FC, Carter JP: A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assn 1990;82:173-177.
3. Cranton EM: Bypassing the Bypass: The New Technique of Chelation Therapy. New York: Stein & Day, 1984.
4. Van der Schaar PJ Jr., van der Shaar PJ: Some in vivo effects of EDTA on platelets. Presented at the Meeting of the American Academy of Medical Preventics, May 25, 1988, Washington, DC.
5. Olszewer E, Carter JP: EDTA chelation therapy in chronic degenerative disease. Med Hypotheses 1988;27:41-49.
6. American College of Advancement in Medicine: Protocol of the American College of Advancement in Medicine for the Safe and Effective Administration of EDTA Chelation Therapy. Laguna Hills, CA: American College of Advancement in Medicine, 1989.
7. Casdorph HR: EDTA chelation therapy: efficacy in atherosclerotic heart disease. J Hol Med 1981;3:53-59.
8. Clarke NE Sr., Mosher RE: Treatment of occlusive vascular disease with disodium thylene diamine tetraacetic acid (EDTA). Am J Med Sci 1960;239:732-744.
9. Kitchell JR, Palmon F, Aytan N, Meltzer L: The treatment of coronary artery disease with disodium EDTA. Am J Cardiol 1963;11:501-506.
10. Olwin JH, Koppel JL: Reduction of elevated plasma lipid levels in atherosclerosis following EDTA therapy. Proc Soc Exp Biol Med 1968;128:1137-1140.
11. Guldager B, Jelnes R, Jorgensen SJ, Nielsen JS, Klaerke A, Mogensen K, et al: EDTA treatment of intermittent claudication: a double-blind, placebo-controlled study. J Intern Med 1992; 231:261-267.
12. Van Rij AM, Solomon C, Packer SGK, Hopkins WG: Chelation therapy for intermittent claudication, a double-blind, randomized, controlled trial. Circulation 1994;90:1194-1199.
13. Mulcahy D, Knight C, Stables R, Fox K: Lasers, burns, cuts, tingles and pumps: a consideration of alternative treatments for intractable angina (editorial). Br Heart J 1994;1:406-407.
14. Marx JJM, Vreugdenhil MD, Voest EE: Iron chelating agents are not useful in treating atherosclerosis (letter). Ann Intern Med 1994;121:384.
15. McCord JM, Day ED Jr.: Superoxide-dependent production of hydroxyl radical catalyzed by iron-EDTA complex. FEBS Lett 1978;86:139-142.
16. Soffer A: Chelation therapy for atherosclerosis. JAMA 1975;233:1206-1208.
17. Wirebaugh SR, Geraets DR: Apparent failure of edetic acid chelation therapy for treatment of coronary atherosclerosis. Drug Intell Clin Pharm 1990;24:22-25.
18. Rathmann KL, Golithly LK: Chelation therapy of atherosclerosis. Drug Intell Clin Pharm 1984;18:1000-1003.
19. Cranton EM: A Textbook on EDTA Chelation Therapy. New York: Human Sciences Press, 1989.
20. Heindorff K, Aurich O, Michaelis A, Rieger R: Genetic toxicology of ethylenediaminetetraacetic acid (EDTA). Mutat Res 1983;115:149-173.
21. Halliwell B, Gutteridge JMC: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984;219:1-14.
22. Halliwell B: Protection against tissue damage in vivo by deferoxamine: what is its mechanism of action? Free Radic Biol Med 1985;7:645-651.
23. Myers CL, Weiss SJ, Kirsh MM, Shlafer M: Involvement of hydrogen peroxide and hydroxyl radical in the "oxygen paradox": reduction of creatine kinase release by catalase, allopurinol or deferoxamine but not superoxide dismutase. J Mol Cell Cardiol 1985;17:675-684.
24. Badvlak SF, Simmons A, Turkek J, Babbs CF: Protection from reperfusion injury in the isolated rat heart by post-ischemic deferoxamine and oxypurinol administration. Cardiovasc Res 1987; 21:500-506.
25. Halliwell B, Gutteridge JM: What is a free radical? In, Halliwell B, Gutteridge JM (eds.): Free Radicals in Biology and Medicine. Second edition. Oxford: Clarendon Press, 1989;10-19.
26. Kloner RA, Przyklenk K, Whittaker P: Deleterious effects of oxygen radicals in ischemia/reperfusion: resolved and unresolved issues. Circulation 1989;80:1115-1127.
27. Halliwell B, Gutteridge JMC: Role of free radicals and catalytic metal ions in human diseae: an overview. In, Packer L, Flazer AN (eds.): Methods in Enzymology. San Diego: Academic Press 1990;1-85.
28. Samokyszyn VM, Reif DW, Miller DM, Aust SD: Effects of cerulo-plasmin on superoxide-dependent iron release from ferritin and lipid peroxidation. Free Radic Res Commun 1991;12-13:153-155.
29. Salonen JT, Nyyssonen K, Heikki K, Tuomilehto J, Seppanen R, Salonen R: High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-811.
30. Van der Kraaij A, Mostert LJ, van Eijk HG, Koster JF: Iron load increases the susceptibility of rat hearts to oxygen reperfusion damage: protection by the antioxidant (+)-cyanidanol-3 and deferoxamine. Circulation 1988;78:442-449.
31. Keberle H: The biochemisty of deferoxamine and its relation to iron metabolism. N Y Acad Sci 1964;119:758-768.
32. Gutteridge JMC, Richmond R, Halliwell B: Inhibition of iron-catalyzed formation of hydroxyls from superoxide and lipid peroxidation by deferoxamine. Biochem J 1979;184:469-472.
33. Menasche P, Grousset C, Mouas C, Piwnica A: Prevention of hydroxyl radical formation: critical concept for improving cardioplegia. Circulation 1987;76:180-185.
34. Menasche P, Grousset C, Piwnica A: A promising approach for improving the recovery of heart transplants: prevention of free radical injury through iron chelation by deferoxamine. J Thorac Cardiovasc Surg 1990;11:13-21.
35. Illes RW, Silverinan NA, Krukenkemp IB, del Nido PJ, Levitsky S: Amelioration of post-ischemic stunning by deferoxamine-blood cardioplegia. Circulation 1989;80:30-35.
36. Ferreira R, Burgos M, Milei J, Llesuy S, Molteni L, Hourquebie H, Boveris A: Effect of supplemental cardioplegic solution with deferoxamine on reperfused human myocardium. J Thorac Cardiovasc Surg 1990;100:708-714.
37. DeBoer DA, Clark RE: Iron chelation in myocardial preservation after ischemia-reperfusion injury: the importance of pretreatment and toxicity. Ann Thorac Surg 1992;53:412-418.
38. Maxwell MP, Hearse DJ, Yellon DM: Inability of desferoxamine to limit tissue injury in the ischaemic and reperfused rabbit heart. J Cardiovasc Pharmacol 1989;13:608-615.
39. Klebanoff SJ, Waltersdorph AM, Michel BR, Rosen H: Oxygen-based free radical generation by ferrous ions and deferoxamine. J Biol Chem 1989;33:19765-19771.
40. Saito M, Thomas CE, Aust SD: Paraquat and ferritin-independent lipid peroxidation. Free Radic Biol Med 1985;1:179-185.
41. Olson RD, Mushlin PS: Doxorubicin-cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990;4:3076-3086.
42. Hershko C, Pinson A, Link G: Prevention of anthracycline cardiotoxicity by iron chelation. Acta Haematol 1996;95:87-92.
43. Cummings J, Anderson L, Willmott N, Smyth JF: The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 1991;27:532-535.
44. Yeung TK, Jaenke RS, Wilding D, Creighton AM, Hopewell JW: The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother Pharmacol 1992;30:58-64.
45. Van Acker SA, Voest EE, Beems RB, Madhulzen HT, de Jong J, Bast A: Cardioprotective properties of O-(β-hydroxyethyl)rutosides in doxorubicin-pretreated balb/c-mice. Cancer Res 1993;53:4603-4607.
46. Herman EH, Zhang J, Ferrans VJ: Comparison of effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 1994;35:93-100.
47. Voest EE, van Acker SA, van der vijgh WJ, van Asbeck BS: Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 1994;26:1179-1185.
48. Kolaric K, Bradamante V, Cervek J, Cieslinska A, Cisarz-Filipcak E, Denisov LE, et al: A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-flourouracil, doxorubicin, and cyclophosphamide. Oncology 1995;52:251-255.
49. Voest EE, Vreugdenhil G, Marx JJM: Iron-chelating agents in non-iron overload conditions. Ann Intern Med 1994;120:490-499.
50. Frishman WH, Sung HM, Yee HCM, Keefe D, Einzig A, Dutcher J: Cardiovascular toxicity with cancer chemotherapy. In, Frishman WH, Sonnenblick EH(eds.): Cardiovascular Pharmacotherapeutics. New York: McGraw Hill, 1997;1479-1503.
51. Frishman WH, Sung HM, Yee HCM, Liu LL, Keefe D, Einzig AI, Dutcher J: Cardiovascular toxicity with cancer chemotherapy (monograph). Curr Probl Cancer 1997;21:301-360.